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Effective humoral immunity depends on the support
of B cell responses by T follicular helper (Tfh) cells.
Although it has been proposed that Tfh cell differen-
tiation requires T-B interactions, the relative contri-
bution of specific populations of Ag-presenting cells
remains unknown. We employed three independent
strategies that compromised interactions between
CD4+ T cells and activated B cells in vivo. Whereas
the expansion of CD4+ T cells was relatively unaf-
fected, Tfh cell differentiation was completely
blocked in all scenarios. Surprisingly, augmenting
antigen presentation by non-B cells rescued Tfh
cell differentiation, as determined by surface pheno-
type, gene expression, and germinal center localiza-
tion. We conclude that although Ag presentation by
responding B cells is typically required for the gener-
ation of Tfh cells, this does not result from the provi-
sion of a unique B cell-derived signal, but rather
because responding B cells rapidly become the
primary source of antigen.
INTRODUCTION
B cell responses, such as germinal center (GC) formation and the
generation of high-affinity long-lived plasma cells and memory
cells, are dependent on help provided byCD4+ T cells. T follicular
helper (Tfh) cells are a specialized subset of T cells that
provide help to B cells (Breitfeld et al., 2000; Schaerli et al.,
2000). Tfh cells are characterized by increased expression of
numerous molecules including the surface markers CXCR5,
PD1, ICOS, and CD40 ligand (CD40L), the cytokine IL-21, and
the transcription factor Bcl-6 (King et al., 2008). These serve
not only as markers of Tfh cells but also play important roles in
their generation and function. The coordinated upregulation of
CXCR5 and downregulation of CCR7 is important for positioning
of Tfh cells in the B cell follicle (Ansel et al., 1999; Hardtke et al.,
2005; Haynes et al., 2007). Similarly, CD40L and IL-21 are potentmodulators of B cell differentiation (Armitage et al., 1992; Bryant
et al., 2007; Ettinger et al., 2005; Noelle et al., 1992; Ozaki et al.,
2002), whereas ICOS-ICOS-ligand (ICOS-L) interactions are
required for eliciting T cell-dependent (TD) B cell responses
(Mak et al., 2003; McAdam et al., 2001; Tafuri et al., 2001).
Several recent studies have also demonstrated that Bcl-6
controls the commitment of CD4+ T cells to a Tfh cell fate in
the same way that Th1, Th2, Th17, and Treg cells are controlled
by T-bet, GATA3, RORgt, and FoxP3, respectively (Johnston
et al., 2009; Nurieva et al., 2009; Yu et al., 2009b).
Uncertainty exists in the steps involved in Tfh cell differentia-
tion, although roles for several different molecules in their gener-
ation have been elucidated. For example, Tfh cells are reduced in
mice deficient in ICOS (Akiba et al., 2005; Bossaller et al., 2006)
and patients with immune deficiencies caused by mutations in
ICOS andCD40LG (Bossaller et al., 2006), suggesting that these
molecules play key roles in their generation and/or maintenance.
It has also been proposed that Tfh cell generation is a multistep
process involving initial activation on dendritic cells (DCs) within
the T cell zone followed by interactions with B cells at the T-B
border or within the follicle (King et al., 2008; Yu et al., 2009a).
X-linked lymphoproliferative disease (XLP) is a rare immuno-
deficiency caused by mutations in SH2D1A, which encodes
SLAM-associated protein (SAP). SAP is an intracellular adaptor
molecule that binds members of the SLAM family of surface
receptors andmediates downstream signaling. The SLAM family
of receptors is widely expressed on hematopoietic cells,
including T and B cells. Both XLP patients and SAP-deficient
mice display impaired TD Ab responses resulting from an
inability of SAP-deficient CD4+ T cells to provide help to B cells
(Crotty et al., 2003; Czar et al., 2001; Hron et al., 2004; Ma
et al., 2005, 2007; Yin et al., 2003). Although several groups
have recently examined Tfh cells in SAP-deficient mice, their
conclusions have been contradictory, with some groups noting
normal Tfh cell development but compromised function (Kam-
perschroer et al., 2008; Qi et al., 2008) yet others observing
impaired development (Cannons et al., 2010; Linterman et al.,
2009). Insight into the mechanism of defective help by SAP-defi-
cient CD4+ T cells was provided by the finding that SAP-deficient
CD4+ T cells had a reduced ability to form stable conjugates with
B cells resulting in dramatically reduced interaction times
between CD4+ T cells and B cells (Qi et al., 2008).Immunity 33, 241–253, August 27, 2010 ª2010 Elsevier Inc. 241
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Ag Determines B Cell Role in Tfh Cell DevelopmentWe sought to clarify the role of SAP in the different stages of
CD4+ T cell activation and Tfh cell development, particularly in
light of the observed defect in T-B interactions. We found that
SAP-deficient CD4+ T cells were incapable of generating normal
numbers of antigen (Ag)-specific Tfh cells, thus revealing an
important role for SAP in Tfh cell development. Similarly, when
Ag was limiting, Ag presentation by activated B cells was
required for Tfh cell generation. Boosting with Ag, however,
could substantially restore this defect inasmuch that CD4+
T cells no longer required Ag presentation by B cells to become
Tfh cells. Rather, this ‘‘rescue’’ of Tfh cell development reflected
ongoing Ag presentation by DCs. Hence, the differences
observed in Tfh cell development in SAP-deficient mice
(Cannons et al., 2010; Kamperschroer et al., 2008; Linterman
et al., 2009; Qi et al., 2008) could be explained by differences
in Ag presentation between DCs and activated B cells.
Thus, this study not only provides an explanation for the
disparate results observed for Tfh cell generation in the absence
of SAP but also demonstrates that the requirement for interac-
tions with B cells during Tfh cell formation reflects Ag availability
rather than a unique B cell-derived activation signal. Together,
our findings reveal an alternative pathway for Tfh cell develop-
ment that is B cell independent.
RESULTS
SAP-Deficient Mice Show a Severe Defect
in the Generation of Tfh Cells
To study the role of SAP in Tfh cell development, SAP-deficient
mice were crossed with mice expressing the OT-II T cell receptor
(TCR),which recognizesovalbumin (OVA).Wild-type (WT)orSAP-
deficient OT-II CD4+ T cells were then transferred into congenic
WT hosts, which were immunized with OVA plus Alum. WT OT-II
cells reached their peak of expansion at day 5, after which their
numbers began to contract (Figure 1A). SAP-deficient OT-II cells
also showedmaximal expansiononday5; however, thedegreeof
expansionwas only half that observed forWT cells (Figure 1A). To
determine the kinetics of Tfh cell formation, expression of CXCR5
and PD1 was examined. Three days after immunization, no
CXCR5hiPD1hi cells were generated from either WT or SAP-defi-
cientOT-II cells. However, by day5 a population ofCXCR5hiPD1hi
(Tfh) cells could be distinguished in theWTOT-II cells (Figures 1B
and1C). Strikingly, this populationwas not seen for SAP-deficient
OT-II cells (Figures 1B and 1C). Thus, whereas WT CD4+ T cells
generated a robust Tfh cell response that peaked around day
5–7 and could still be observed at day 10, SAP-deficient CD4+
T cells were largely unable to form Tfh cells.
Next, we studied changes in expression of ICOS and CCR7,
which are also associated with CD4+ T cell activation. Early in
the response, before CXCR5hiPD1hi cells appear, WT and
SAP-deficient OT-II cells downregulated CCR7 (Figure 1D) and
upregulated ICOS (Figure 1E) to a similar degree. Although
SAP-deficient CD4+ T cells failed to generate Tfh cells by day 7,
their expression of ICOS was similar to WT OT-II cells (Figure 1E)
and they maintained substantial CCR7 downregulation (Fig-
ure 1D). Hence, early activation events are intact in SAP-defi-
cient CD4+ T cells.
Tfh cells are characterized not only by expression of CXCR5
and PD1 but also by altered expression of other markers242 Immunity 33, 241–253, August 27, 2010 ª2010 Elsevier Inc.(King et al., 2008). Thus, to better understand the development
of Tfh cells, their phenotype was determined (Figure S1 available
online). As previously described (Chtanova et al., 2004; Kim
et al., 2004; Ma et al., 2009; Rasheed et al., 2006), they ex-
pressed high amounts of CXCR4, ICOS, CD200, and CD272
(BTLA), although these latter three were upregulated on all WT
OT-II cells, albeit to a slightly lower degree than on Tfh cells.
Tfh cells also showed decreased expression of CCR7, CD62L,
and CD127 (IL-7Ra). Importantly, the SLAM family members
SLAM, CD84, and Ly108 were present on activated OT-II cells
(both non-Tfh and Tfh cells) at higher amounts than on endoge-
nous (mostly naive) CD4+ T cells.
We next determined whether the detection of CXCR5hiPD1hi
cells corresponded with the appearance of OT-II cells in the B
cell follicle. At day 3, the majority of WT and SAP-deficient
OT-II cells localized to the T cell zone while only a few were
observed in the follicle (Figure 1F). By day 7, GCs were estab-
lished andWT OT-II cells could be found within these structures,
in addition to the T cell zone and B cell follicle. In contrast,
SAP-deficient OT-II cells could not be found in the GC (Figures
1F and 1G), with the majority of them remaining in the T cell
zone. Thus, both phenotypic and histological analyses demon-
strated that SAP-deficient T cells failed to form Tfh cells, partic-
ularly those localizing to GCs.
Restoring GCs Does Not Induce Tfh Cell Development
from SAP-Deficient CD4+ T Cells
Although we could find GCs in mice receiving SAP-deficient
OT-II cells, GC formation was reduced compared to mice that
received WT OT-II cells (Figures 2A and 3D). These residual
GCs observed in mice receiving SAP-deficient OT-II cells are
largely supported by the endogenous SAP-sufficient CD4+
T cells that also respond toOVA, as demonstrated by a consider-
able decrease in GC cells when OT-II cells were transferred into
SAP-deficient recipients (Figure S2). Thus, it was possible that
the lack of GC-related Tfh cell development was secondary to
poor GC development, and a reduction in GC B cells, to support
these Tfh cells. This scenario would be consistent with the
proposed role of B cells in providing appropriate signals for Tfh
cell development (King et al., 2008; Yu et al., 2009a). To test
this possibility, Thy1.1WT or Thy1.1+ SAP-deficient OT-II cells
were transferred either separately or together into CD45.1-con-
genic recipients followed by challenge with OVA plus Alum. The
cotransfer of WT OT-II cells was able to rescue the poor GC
response induced by SAP-deficient OT-II cells as measured by
the presence of IgG1+GL7+ cells (Figure 2A). Nevertheless,
SAP-deficient CD4+ T cells still showed decreased expansion
(Figure 2B) and the increased GC response did not induce
formation of CXCR5hiPD1hi Tfh cells from SAP-deficient CD4+
T cells (Figures 2C and 2D). Therefore, defective formation of
Tfh cells in the absence of SAP is not merely a consequence of
the lack of a strong GC response.
SAP-Deficient T Cells Can Differentiate into Tfh Cells
after Boosting with Specific Ag
Several phenotypic markers of Tfh cells, such as high PD1 and
CXCR5 expression and low CD127 expression, have been asso-
ciated with ongoing T cell activation (Franchimont et al., 2002;
Hammerbeck and Mescher, 2008), suggesting that Tfh cells
Figure 1. SAP Deficiency Severely Compromises the Development of Tfh Cells
WT or Sh2d1a/ (SAP KO) OT-II cells were transferred to congenic recipients that were then immunized with OVA plus Alum i.p.
(A) The proportion of OT-II cells in the spleen was determined at various times (mean ± SEM, n = 5–14).
(B and C) Cells were stained for CXCR5 and PD1 and the number of CXCR5hiPD1hi cells was determined (mean ± SEM, n = 5–14).
(C) Contour plots show CXCR5 and PD1 expression on OT-II cells on days 3 (left) and 7 (right) postimmunization.
(D and E) Cells were stained for CCR7 (D) or ICOS (E). Histograms show CCR7 or ICOS expression on endogenous CD4+ T cells (gray) and OT-II cells (red) after 3
(top) or 7 (bottom) days.Graphs show relative change in expressionofCCR7and ICOSonOT-II cells compared to endogenousCD4+Tcells (mean±SEM, n=7–8).
(F) Immunofluorescence staining of spleen sections was carried out to determine the positioning of OT-II T cells (CD45.2+) within the follicle (IgD) and T cells zone
(CD4) after 3 (left) or 7 (right) days.
(G) Further staining confirmed positioning within the GC (PNA) at day 7.
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Figure 2. RescuingGerminal Center Forma-
tion Does Not Facilitate Tfh Cell Develop-
ment from SAP-Deficient CD4+ T Cells
CD45.1-congenic mice were transferred with
CD45.2+ OT-II cells. Mice received either
Thy1.1 WT OT-II or Thy1.1+ SAP KO OT-II alone
or a combination of equal numbers of Thy1.1
WT OT-II or Thy1.1+ SAP KO OT-II and were
then immunized i.p. with OVA plus Alum. The
responses were examined 7 days later.
(A) The proportion of IgG1+GL7+ (GC) B cells in
recipient spleens.
(B) The proportion of OT-II cells from each donor
was determined. WT OT-II, filled bars; SAP KO
OT-II, open bars.
(C) The proportion of CXCR5hiPD1hi Tfh cells from
each donor was determined. All graphs show
mean ± SEM, n = 4.
(D) Contour plots show expression of CXCR5 and
PD1 on OT-II cells of each genotype.
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Ag Determines B Cell Role in Tfh Cell Developmentmay require sustained stimulation for their development or main-
tenance. Therefore, we determined whether the provision of a
second dose of Ag might restore Tfh cell development from
SAP-deficient CD4+ T cells. Accordingly, some mice were given
OVA peptide 3 days after the primary OVA plus Alum challenge.
Mice receiving the peptide boost showed increased numbers of
OT-II cells regardless of whether or not the transferred cells
expressed SAP (Figure 3A). More strikingly, this peptide boost
dramatically restored Tfh cell development from SAP-deficient
precursors such that the number of CXCR5hiPD1hi CD4+
T cells approached that seen for WT cells in recipients immu-
nized with OVA plus Alum alone (Figures 3B and 3C). This rescue
of CXCR5hiPD1hi Tfh cells was not associated with an increase in
GC B cells (Figure 3D), nor a substantial change in downregula-
tion of CD62L (Figures 3E and 3F). This second dose of Ag did,
however, result in an increase in the proportion of cells that
downregulated CD127 (Figures 3G and 3H). The increase in
CD127lo cells was particularly prominent in the SAP-deficient
OT-II population, which had less than half the WT numbers of
CD127lo cells if they received only OVA plus Alum, but reached
approximately 90% of WT numbers after the boost. Because
loss of CD127 is associated with sustained TCR signaling
(Franchimont et al., 2002; Hammerbeck and Mescher, 2008),
SAP-deficient T cells may lack the persistent Ag stimulation
necessary for Tfh cell formation.
SAP-Deficient Tfh Cells Express Bcl-6 and Localize
to Germinal Centers
Although boosting with peptide increased the number of
CXCR5hiPD1hi cells, it was necessary to determine whether
these cells possessed other characteristics of Tfh cells such as
localization within the follicle and GC and expression of Tfh
cell-associated genes. This was particularly important, because
the maximum degree of CXCR5 and PD1 expressed by WT and
SAP-deficient OT-II cells after the peptide boost was decreased
compared to WT cells that had not received the boost (Fig-
ure 3C). In contrast to the initial OVA plus Alum challenge, in244 Immunity 33, 241–253, August 27, 2010 ª2010 Elsevier Inc.which no SAP-deficient cells were found in the GCs (Figures 1F
and 1G), after peptide boost both WT and SAP-deficient OT-II
cells were detected in the follicle and the GC (Figure 3I). Thus,
in terms of positioning within secondary lymphoid tissues, these
cells generated from SAP-deficient CD4+ T cells after peptide
boost appear to be bona fide Tfh cells.
The Tfh cell phenotype has also been associated with expres-
sion of the transcription factor Bcl-6 (Chtanova et al., 2004; Kim
et al., 2004; Rasheed et al., 2006). Therefore, we isolated the
three different subsets of OT-II cells (Figure 3J) generated in
response to OVA plus Alum with or without the peptide
boost—CD62Lhi, CD62LloPD1lo, and CD62LloPD1hi (i.e., Tfh
cells)—and determined their expression of Bcl6 (Figure 3K).
Irrespective of the immunization strategy and genotype of the
transferred OT-II cells, high expression of Bcl6 was detected
only in the CD62LloPD1hi population (Figure 3K). This confirmed
that the inability of SAP-deficient OT-II cells to form Tfh cells in
the absence of the peptide Ag boost was not simply a conse-
quence of a lack of surface CXCR5 and PD1 expression but
also a failure to upregulate the Tfh cell ‘‘master regulator’’
Bcl-6. Interestingly, even though the peptide-boosted OT-II cells
displayed reduced amounts of PD1 and CXCR5 compared to
those responding to OVA plus Alum alone, Bcl-6 expression by
Tfh (i.e., CD62LloPD1hi) cells generated by these different immu-
nization strategies was similar. We also examined expression of
IL-21 and SAP in the sorted populations. We found high Il21
expression in all of the CD62LloPD1hi populations, consistent
with a Tfh cell phenotype. However, we also observed elevated
Il21 in the CD62Lhi and CD62LloPD1lo populations frommice that
received a peptide boost (Figure 3L). Sh2d1a (encoding SAP)
expression was also upregulated in the WT CD62LloPD1hi popu-
lations (Figure 3M), consistent with previous reports of increased
expression of SAP mRNA or protein in Tfh cells (Chtanova et al.,
2004; Ma et al., 2009; Rasheed et al., 2006).
Thus, although in the absence of SAP there is a paucity of Tfh
cells, this deficiency can be partially rescued by the provision
of peptide Ag. This rescue was not limited to peptide Ag alone;
Immunity
Ag Determines B Cell Role in Tfh Cell Developmentit was also achieved by boosting with whole OVA protein (Fig-
ures S3A and S3B) or peptide-pulsed in vitro activated B cells
(data not shown). Interestingly, in both of these alternate boost-
ing protocols, the effect on WT cells was superior than with
peptide, thereby resulting in a much greater difference in the
generation of Tfh cells between WT and SAP-deficient cells
(Figures S3A and S3B). Consistent with the ability of SAP-defi-
cient T cells to develop into Tfh cells if sufficient Ag is available,
we also observed less severe defects in the numbers of SAP-
deficient Tfh cells in response to alternative immunization strat-
egies (Figures S3C and S3D). Similarly, Tfh-like CD4+CXCR5+
cells could be detected in the blood of XLP patients (Figure S3E).
Peptide Boost Overcomes the Requirement for B Cell
Activation via CD40 for Tfh Cell Development
What does this ability of Ag boost to rescue SAP-deficient CD4+
T cells reveal about the generation of Tfh cells in general? It was
recently shown that SAP-deficient CD4+ T cells are able to
interact normally with DCs but not B cells (Qi et al., 2008). This
is consistent with our observation that initial activation of SAP-
deficient T cells, such as expansion, ICOS upregulation, and
CCR7 downregulation, was relatively normal. Thus, one explana-
tion for the reduced expansion, CD127 downregulation, and Tfh
cell development observed at later time points for SAP-deficient
CD4+ T cells is that there is a lack of ongoing Ag stimulation that
would normally be provided by activated Ag-presenting B cells.
To more closely examine the role of B cells in Tfh cell develop-
ment, we generated mixed BM chimeras in which the B cells
lacked CD40 (mMT:Cd40/) and therefore could not be acti-
vated by CD40L-expressing CD4+ T cells, but CD40+ DCs
were present (Figure 4A; Figure S4A). Chimeras received WT
OT-II cells and were challenged with OVA plus Alum with or
without the peptide boost. In mice that did not receive peptide
boost, we observed similar expansion of OT-II cells regardless
of whether the B cells expressed CD40 (Figure 4B). However,
in the absence of CD40+ B cells, there was a complete absence
of Tfh cells (Figures 4C and 4D). This was associated with a lack
of GC B cells (Figure 4E), consistent with the need for CD40L-
CD40 interactions for TD B cell responses (Renshaw et al.,
1994; Xu et al., 1994).Whenmice received a peptide boost, there
was an increase in the number of OT-II cells recovered. Strik-
ingly, this was associated with the appearance of CXCR5hiPD1hi
Tfh cells in the mMT:Cd40/ chimeras, although GCs still failed
to be generated. In contrast, the peptide boost was unable to
efficiently rescue Tfh cell development from CD40L-deficient
OT-II cells (Figures S4B–S4G), indicating that CD40L:CD40
interactions, with either B cells or other APC, are required for
Tfh cell development. OT-II cells in the mMT:Cd40/ chimeric
mice also showed decreased CD127 downregulation in
response to OVA plus Alum alone; however, this could be
increased by peptide injection (Figure 4F) mirroring the observa-
tions for SAP-deficient OT-II cells (Figure 3H). Thus, Tfh cells
could be generated independently of TD B cell activation and
GC formation when mice received an Ag boost.
B Cell-Mediated Ag Presentation Is Not Required for Tfh
Cell Development in the Presence of Excess Ag
These results with the mMT:Cd40/chimeras suggested that B
cells may not be as critical to Tfh cell development as previ-ously suggested. Therefore, we generated another set of mixed
BM chimeras in which the B cells—but not DCs—lacked all
MHC class II (MHC II) genes and were therefore incapable of
presenting Ag to CD4+ T cells (Figure 5A). As expected, OT-II
cells transferred into B6:MHCII-deficient control chimeras
expanded and formed Tfh cells in response to OVA plus Alum
(Figures 5B–5D) and these numbers were further increased
after peptide boost. Moreover, these mice developed strong
GC responses (Figure 5E). In contrast, when B cells were
unable to present Ag (i.e., mMT:MHCII-deficient chimeras), the
generation of Tfh cells in response to OVA plus Alum alone
was abolished (Figures 5C and 5D). This lack of Tfh cell devel-
opment was associated with a reduced proportion of CD127lo
cells (Figure 5F). The peptide boost at day 3, however, induced
greater downregulation of CD127 and was able to restore
formation of Tfh cells in these mice as judged by surface
phenotype (Figure 5D) and Bcl6 expression (Figure S5C).
Boosting with whole OVA was able to rescue Tfh cell develop-
ment in a similar manner (Figures S5A and S5B). Thus,
responses of WT OT-II CD4+ T cells in the absence of B cell-
mediated Ag presentation replicated responses of SAP-defi-
cient OT-II cells, which is consistent with the reduced ability
of SAP-deficient CD4+ T cells to interact with B cells (Qi
et al., 2008). More strikingly, this result reveals that Tfh cell
formation does not strictly require Ag presentation by B cells,
but rather can be driven by other APCs when there is abundant
Ag. This is further supported by the finding that Tfh-like
CD4+CXCR5+ cells can be detected in the blood of B cell-defi-
cient patients with X-linked agammaglobulinemia resulting from
mutations in BTK (Figure S5D).
Limited Ag Presentation by DCs Is Extended by Peptide
Boost
Our data with mixed BM chimeric mice extend that of other
groups that have established a key role for B cells in Tfh cell
generation under conditions of limiting Ag (Haynes et al., 2007;
Johnston et al., 2009; Zaretsky et al., 2009). Because Tfh cells
could be formed in the presence of excess Ag when Ag presen-
tation by B cells was abolished, we hypothesized that DCs were
responsible for prolonged Ag presentation (and thus Tfh cell
development) after the peptide boost. To test this, we immunized
mice and then boosted some with peptide. Two days later, we
determined whether there was ongoing Ag presentation by
sorting DCs and culturing them with naive CFSE-labeled OT-II
cells. When peptide was added to the in vitro cultures, DCs
from all three groups of mice could promote proliferation,
demonstrating that all the DCs had equal APC capabilities
(Figures 6A and 6B). In contrast, only DCs isolated from mice
that received the peptide boost induced OT-II cell proliferation
in the absence of exogenous peptide. Peptide boost did not
result in prolonged Ag presentation by all MHC class II-express-
ing cells as indicated by the fact that nonactivated B cells from
boosted mice did not induce proliferation of OT-II cells in the
absence of exogenous peptide (Figure S6). Thus, injection of
Alum plus OVA i.p. results in only brief Ag presentation by DCs
that can no longer be detected by day 6. However, expression
of peptide:MHCII complexes can be prolonged by i.v. adminis-
tration of peptide, thereby facilitating ongoing stimulation of
CD4+ T cells on DCs.Immunity 33, 241–253, August 27, 2010 ª2010 Elsevier Inc. 245
Figure 3. Treatment with Peptide Can Rescue Tfh Cell Development from SAP-Deficient T Cells
WT or SAP KO OT-II cells were transferred to congenic recipients that were then given OVA plus Alum i.p. at day 0. On day 3 somemice received additional OVA
peptide i.v. and the mice then sacrificed on day 7.
(A) The proportion of total OT-II cells in the spleen.
(B and C) The proportion of CXCR5hiPD1hi Tfh OT-II cells (B) was determined by staining (C) for CXCR5 and PD1 on OT-II cells.
(D) Proportion of GC B cells as determined by staining for expression of GL7 and Fas.
(E) Expression of CD62L and PD1 on OT-II cells.
(F) Percentage of OT-II cells that are CD62Llo.
(G) Expression of CD127 and PD1 on OT-II cells.
(H) Percentage of OT-II cells that are CD127lo.
(A–H) All graphs show mean ± SEM, n = 7–9, except (F), n = 4–6.
(I) Immunofluorescence staining of spleen sections was performed to determine the positioning of OT-II T cells (CD45.2+) within the follicle (IgD) and GC (PNA).
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Figure 4. B Cell Activation via CD40 Is Not Required for Tfh Cell Development
Chimeras were generated as described in Experimental Procedures (see also Figure S4A) via 80:20mix of mMT:Cd40/BM (to generatemice with B cells lacking
CD40) or B6:Cd40/BM (controls). Thy1.1+WTOT-II cells were transferred into the chimeras, which were then given OVA plus Alum i.p. at day 0. On day 3 some
mice received additional OVA peptide i.v. and the mice were sacrificed on day 7 for analysis.
(A) Reconstitution was determined by staining B cells (B220+) and DCs (CD11c+) for CD40 expression.
(B) The proportion of total OT-II cells in the spleen.
(C and D) The proportion of CXCR5hiPD1hi Tfh OT-II cells (C) was determined by (D) staining for CXCR5 and PD1 on OT-II cells.
(E) Proportion of GC B cells as assessed by staining for expression of GL7 and Fas.
(F) Percentage of OT-II cells that are CD127lo.
All plots show mean ± SEM, n = 7–14.
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Ag Determines B Cell Role in Tfh Cell DevelopmentBoosting the Tfh Response Has Limited Effect
on the B Cell Response
TD B cell responses require the generation and function of Tfh
cells. It is unclear, however, whether increasing the number of
Tfh cells is sufficient to increase the subsequent Ab response.
Indeed, a recent study found that dramatically increasing the
generation of Tfh cells by ectopically expressing Bcl6 in naive
CD4+ T cells only augmented the Ag-specific B cell response
by 2-fold (Johnston et al., 2009). Thus, we examined the
effect that boosting with peptide (and thus increasing the
number of Ag-specific Tfh cells) would have on the B cell
response. OT-II CD4+ T cells and hen egg lysozyme (HEL)-
specific B cells (SWHEL) were adoptively transferred into recip-
ient mice that were then challenged with HEL coupled to OVA
peptide (HEL-OVApep). In order to also study any effect on
affinity maturation, we used a variant of HEL (HEL2X) that has
approximately 200 times lower affinity for the transgenic B
cell receptor than WT HEL (Paus et al., 2006). Boosting the(J–M) CD62Lhi, CD62LloPD1lo, and CD62LloPD1hi populations of OT-II CD4+ T cells
andSh2d1a (M) in each of these populations was then determined by quantitative
for peptide boost, three experiments for nonboost.mice with OVA peptide at days 3 and 6 resulted in a significant
increase in both total OT-II cells (p = 0.0003) and OT-II Tfh cells
(p = 0.0074) at day 10 (Figures 7A and 7B). However, even
though Tfh cell numbers were augmented, no increase in the
total number of HEL-binding B cells (Figure 7C), nor in the titers
of serum anti-HEL IgG1 (Figure 7D), were observed. Because
boosting Tfh cell numbers may alter the quality of the
response, we stained the responding B cells with a different
variant of HEL (i.e., HEL3X) that identifies cells that had under-
gone affinity maturation (Figure 7E; Paus et al., 2006). This
staining revealed that affinity maturation of the major isotype
switched population (IgG1) was unaltered after peptide boost
(Figure 7F). Similarly, titers of affinity-matured IgG1 in the
serum were not altered (Figure 7G). Thus, boosting Tfh cells
during the course of an ongoing Ab response has little effect
on the outcome of Ab production, suggesting that the initial
immunization in this case had already produced optimal
numbers of these cells.(CD4+B220CD45.2+) were isolated by sorting. Expression ofBcl6 (K), Il21 (L),
PCR. N.D., not done. The values represent themean ± SEM of four experiments
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Figure 5. B Cell Ag Presentation Is Not Required for Tfh Cell Development
Chimeras were generated as described in Experimental Procedures with 80:20 mix of mMT:MHCII-deficient BM (to generate mice with B cells lacking MHC class
II) or B6:MHCII-deficient BM (controls). Thy1.1+ WT OT-II cells were transferred into the chimeras, which were then given OVA plus Alum i.p. at day 0. On day 3
some mice received additional OVA peptide i.v. and the mice were sacrificed on day 7 for analysis.
(A) Reconstitution was determined by staining B cells (B220+) and DCs (CD11c+) for MHCII expression.
(B) The proportion of total OT-II cells in the spleen.
(C and D) The proportion of CXCR5hiPD1hi Tfh OT-II cells (C) was determined by staining (D) for CXCR5 and PD1 on OT-II cells.
(E) Proportion of GC B cells as assessed by staining for expression of GL7 and Fas.
(F) Percentage of OT-II cells that are CD127lo. All plots show mean ± SEM, n = 6–8.
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Ag Determines B Cell Role in Tfh Cell DevelopmentDISCUSSION
The generation of Tfh cells is crucial to the development of long-
lived effector B cells. Dysregulated Tfh cell development and/or
function has been associatedwith both immune deficiencies and
autoimmune diseases (King et al., 2008). Consequently, it is
important to understand the mechanisms that regulate the
differentiation of naive CD4+ T cells to a Tfh cell fate. Recent
studies have identified requirements for CD40-CD40L, ICOS-
ICOS-L (Akiba et al., 2005; Bossaller et al., 2006; Nurieva et al.,
2008), IL-21 (Nurieva et al., 2008; Vogelzang et al., 2008), IL-6
(Eddahri et al., 2009; Nurieva et al., 2008), and B cells (Haynes
et al., 2007; Johnston et al., 2009; Zaretsky et al., 2009) in Tfh
cell formation. However, many uncertainties about the differenti-
ation pathway of Tfh cells remain. For instance, the relative roles
of DCs and B cells in inducing Tfh cell differentiation are unclear,
and the role of IL-21 is controversial (Bessa et al., 2010;
Linterman et al., 2010; Nurieva et al., 2008; Vogelzang et al.,
2008; Zotos et al., 2010). Initial activation of T cells occurs on
DCs within the T cell zone. This interaction is thought to induce
the concomitant upregulation of CXCR5 and downregulation of248 Immunity 33, 241–253, August 27, 2010 ª2010 Elsevier Inc.CCR7, which mediates the migration of T cells to the T-B border
or follicle (Ansel et al., 1999; Hardtke et al., 2005; Haynes et al.,
2007). Indeed, it has been shown that entry of CD4+ T cells into
the follicle can occur independently of interactions with B cells
(Fillatreau and Gray, 2003).
After this initial activation of CD4+ T cells by DCs, however,
subsequent interactions with B cells are suggested to provide
the requisite signals for Tfh cell development (King et al.,
2008). A key role for B cells in inducing Tfh cells is supported
by several studies inwhich Tfh cell numberswere severely dimin-
ished in mice where B cells were absent or unable to present Ag
to the responding CD4+ T cells (Haynes et al., 2007; Johnston
et al., 2009; Zaretsky et al., 2009). Such a two-stage model of
Tfh cell development raises the question of what the unique
signal is that B cells provide to induce Tfh cell differentiation.
For example, it was recently shown that in the absence of
ICOS-L expression by B cells, Tfh cell numbers were reduced
(Nurieva et al., 2008). However, because many other cells—
including DCs—also express ICOS-L (Aicher et al., 2000), this
does not fulfill the role of a unique B cell-specific signal. We
also observed a severe defect in Tfh cell development after
Figure 6. Peptide Boost Prolongs Ag Presentation by DCs
Micewere given Alum or OVA plus Alum i.p. at day 0. At day 4mice somemice received additional OVA peptide i.v. On day 6 themice were sacrificed and spleens
removed. CD11c+ cells were isolated by cell sorting and were placed in culture with CFSE-labeled OT-II cells to detect presentation of OVA peptide. Cultures
were harvested 3 days later and OT-II cells identified by staining for CD4.
(A) Representative CFSE profiles of OT-II cells.
(B) Plots show percentage of cells that are in division (mean ± range of two experiments).
Immunity
Ag Determines B Cell Role in Tfh Cell Developmentimmunization of mice whose B cells were unable to present Ag.
However, Tfh cell development could be rescued when these
same mice were boosted with OVA peptide. This demonstrates
that B cells do not express a unique set of costimulatory mole-
cules or soluble signals that are required for Tfh cell generation.Figure 7. Effect of Peptide Boost on B Cell Responses
WT congenic mice received WT or SAP KO OT-II cells in combination with W
HEL2X-OVApep. Some mice received additional peptide at days 3 and 6. Mice we
(A and B) The proportions of total OT-II cells (A) and CXCR5hiPD1hi Tfh OT-II cel
(C) Splenocytes were stained for CD45.1 and CD45.2 to detect donor cells and
(D) The titers of anti-HEL IgG1 in the serum were measured by ELISA against HE
(E) The proportion of IgG1-switched cells of high affinity was determined by sta
CD45.2) that are IgG1+. Numbers show proportion of cells that bind HEL3X with
(F) Graphs show proportion of IgG1+ SWHEL cells that had undergone affinity matu
each experiment).
(G) The degree of affinitymatured anti-HEL in the serumwas determined by coatin
from multiple experiments.Rather, these data suggest that other APCs, namely DCs, can
drive Tfh cell development autonomously.
We were able to demonstrate that boosting mice with peptide
prolonged Ag presentation by DCs. Thus, our findings imply that
non-B cell APCs possess all of the signals required for inducingT SWHEL cells. Mice were immunized i.p. with OVA plus Alum and i.v. with
re sacrificed at day 10 and spleens removed.
ls (B) were determined.
the proportion of total HEL-binders was determined by staining with HELWT.
LWT.
ining for with HEL3X. Plots show donor SWHEL cells (gated with CD45.1 and
high affinity (i.e., cells that have undergone affinity maturation).
ration (numbers are expressed relative to the average of nonboosted controls in
g plates with HEL4X. All plots showmean ±SEMof at least 12 animals combined
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Ag Determines B Cell Role in Tfh Cell DevelopmentTfh cells, but the limiting factor is Ag availability. Tfh cells
possess many hallmarks of cells receiving strong TCR stimula-
tion, such as expression of CXCR5, PD1, IL-21, and downregu-
lation of CD127 (Franchimont et al., 2002; Hammerbeck and
Mescher, 2008). Recent work has also suggested a role for Ag
affinity in Tfh cell generation (Fazilleau et al., 2009). These find-
ings are consistent with the idea that Tfh cell development
and/or maintenance requires ongoing Ag stimulation. Hence,
the ability of any APC to direct Tfh cell differentiation will be
determined by its ongoing capacity to present Ag. In conditions
of limiting Ag availability, it would be predicted that B cells would
have an advantage over other APCs in the acquisition of Ag
because of the ability of the high-affinity BCR to efficiently take
up Ag (Macaulay et al., 1997) and their access to Ag depots in
the form of immune complexes on FDC (Szakal et al., 1989).
This model also provides an explanation for the range of
results observed for Tfh cell development in SAP-deficient
mice. Whereas some groups have reported relatively normal
Tfh cell development (Kamperschroer et al., 2008; Qi et al.,
2008), others observed a substantial numerical defect (Cannons
et al., 2010; Linterman et al., 2009). We also observed varying
severity in the defect in Tfh cell numbers depending on the immu-
nization strategy used. SAP-deficient CD4+ T cells are unable to
form stable conjugates with B cells (Qi et al., 2008). Strikingly, we
were able to modulate whether or not Tfh cells developed
from SAP-deficient CD4+ T cells by using different immunization
strategies that altered the amount of Ag presented by DCs. Thus,
the spectrum of Tfh cell responses seen in SAP-deficient mice
probably reflects the relative ratio of B cell to DC Ag presentation
with models that show relatively normal Tfh cells representing
situations where APCs other than B cells continue to present
Ag for extended periods of time. An example of this is the finding
of normal frequencies of Tfh cells in SAP-deficient mice infected
with influenza virus, a setting that would presumably result in
persistent Ag presentation by multiple types of APCs (Kampers-
chroer et al., 2008). It is important to note that regardless of
the increased generation of Tfh cells with increased Ag, these
SAP-deficient CD4+ cells continued to be unable to support
robust B cells responses, as evidenced by a lack of GC and
Ag-specific Ab responses (Crotty et al., 2003; Czar et al., 2001;
Hron et al., 2004; Ma et al., 2007; Yin et al., 2003), because of
their inability to interact with the B cells to provide appropriate
helper signals (Qi et al., 2008). This may explain the normal
frequencies of circulating CXCR5+ Tfh-like cells in XLP patients
despite the inability of these patients to elicit efficient TD Ab
responses in vivo and their CD4+ T cells to provide help to B cells
in vitro (Ma et al., 2005, 2006).
IL-21 has also been shown to be expressed by Tfh cells (Chta-
nova et al., 2004; Nurieva et al., 2008) andmay have a role in their
development (Nurieva et al., 2008; Vogelzang et al., 2008). Inter-
estingly, we showed that a peptide boost was able to not only
induce formation of IL-21-producing Tfh cells fromSAP-deficient
cells but also to increase IL-21 production from all responding
OT-II cells. Thus, it is conceivable that part of the ability of the
peptide boost to rescue Tfh cell development is due to the ability
of the increased TCR signaling to increase the amount of IL-21
available to the differentiating cells (Fazilleau et al., 2009).
Regulation of Tfh cell development is critical for generating
appropriate B cell responses. Our studies shed further light on250 Immunity 33, 241–253, August 27, 2010 ª2010 Elsevier Inc.the mechanisms involved in their generation. Importantly, they
reveal the role of ongoing Ag stimulation, which has particular
relevance to situations of chronic Ag exposure, such as autoim-
munity, where it has been shown that Tfh cell numbers are
increased (Hu et al., 2009; Victoratos and Kollias, 2009; Vinuesa
et al., 2005). Further, they reveal the ability of DCs to fully drive
Tfh cell development from naive CD4+ T cells even in the
absence of T-B cell interactions. Surprisingly, however, we
found that increasing Tfh cells was not sufficient to boost Ab
production. This may be because the GC response in the model
investigated is already ‘‘saturated’’ with Tfh cells and thus further
increasing Tfh cell numbers has no discernable effect on the
behavior of the B cells. Therefore, in cases where it might be
desirable to boost Ab responses, such as vaccination, boosting
Tfh cell numbers may only be an effective strategy when this
component of the response is suboptimal, for example in immu-
nocompromised individuals or immunodeficient conditions
where Tfh cell generation is affected.
EXPERIMENTAL PROCEDURES
Mice
OT-II (Barnden et al., 1998), SWHEL (Phan et al., 2003), MHCII-deficient (Mad-
sen et al., 1999), Cd40/ (Kawabe et al., 1994), Sh2d1a/ (Czar et al., 2001),
Cd40lg/ (Renshaw et al., 1994), Icos/ (Tafuri et al., 2001), and Igh-6/
(i.e., mMT) (Kitamura et al., 1991) mice were on C57BL/6 backgrounds and
have been described previously. Mice were bred and housed in specific path-
ogen-free conditions in the Garvan Institute Biological Testing Facility or
Australian BioResources. C57BL/6 and SJL-Ptprca (CD45.1 congenic)
C57BL/6 mice were purchased from the Animal Resources Centre or Austra-
lian BioResources. Experiments were approved by the Garvan Institute-St.
Vincent’s Animal Experimentation Ethics Committee.
OT-II Adoptive Transfers
For OT-II experiments, spleen cells containing 33 104 Va2+CD4+ OT-II T cells
were injected i.v. into recipient mice. Recipient mice were also immunized i.p.
with 100 mg of OVA (Sigma-Aldrich) in Alum (Pierce) on the day of transfer.
For BM chimera experiments, CD4+ T cells were negatively selected from
OT-II splenocytes with a MACS CD4+ isolation kit (Miltenyi). Some mice also
received 10 mg of OVA323–339 peptide (Mimotopes) intravenously.
Immunofluorescence Histology
Sections (6–7 mm) were cut with a Leica CM1900 cryostat, fixed in acetone,
and blocked with 30% normal horse serum. T cells were stained with anti-
CD4 FITC, follicular B cells with anti-IgD Alexa Fluor 647, and GCs with
PNA-FITC (Vector Laboratories), and OT-II transgenic T cells were detected
with anti-CD45.2 biotin, followed by SA-A555 (Invitrogen). Slides were
analyzed with a Zeiss Axiovert 200M microscope and Adobe Photoshop
software.
Quantitative PCR
Spleens were taken from mice and stained for sorting. OT-II cells were
identified as CD4+ B220 CD45.2+. Three different populations of OT-II cells
were sorted based on CD62L and PD1 expression with a FACSAria or FACS-
Vantage (BD). RNA was extracted with QIAGEN RNeasy kit and transcribed
into cDNA with SuperScript III via first strand synthesis protocol by Invitrogen.
Expression of Bcl6, Il21, and Sh2d1a was then determined by real-time PCR
with the Roche LightCycler 480 Probe Master Mix and System. All real-time
PCR primers were from Integrated DNA Technologies and designed with
Roche UPL Primer Design Program. All reactions were standardized to the
expression of GAPDH.
Bone Marrow Chimeras
SJL-Ptprca (CD45.1 congenic) recipients were lethally irradiated (2 doses of
425 rads 4 hr apart) with an X-ray irradiator (General Electric). Mice then
Immunity
Ag Determines B Cell Role in Tfh Cell Developmentreceived an 80/20 mix of B6/MHCII-deficient, Igh-6//MHCII-deficient,
B6/ Cd40/, or Igh-6//Cd40/ BM cells (6–10 3 106 cells) intravenously.
Mice were allowed to reconstitute for at least 8 weeks before experiments
were performed. Reconstitution was tested by staining for CD45.1, B220,
CD11c, CD40, and MHCII.
Isolation of DCs and In Vitro Ag Presentation Assay
Spleens were removed and digested in Collagenase D (Roche) for 30 min at
37C. RBCs were removed by centrifugation over Ficoll and cells were stained
for CD11c and B220. CD11c+B220+ cells were sorted with a FACSAria or
FACSVantage (BD). CD4+ cells were isolated from the spleens of OT-II mice
with a MACS CD4+ selection kit (Miltenyi) and were labeled with 5 mM CFSE.
43104CD11c+cellswere cultured togetherwith 53104OT-II cells in 96-round
bottom plates. To some cultures, 3 mM OVA323–339 was added. 3 days later,
cells were harvested, stained for CD4, and run on a flow cytometer.
SWHEL Experiments
Production of recombinant HEL proteins and adoptive transfer procedures
have been described previously (Paus et al., 2006). For collaborative
responses between SWHEL B cells and OT-II T cells, HEL
2X was chemically
conjugated to OVA323–339 peptide (CGGISQAVHAAHAEINEAGR) with the
cross-linking agent succinimidyl-6- [b-maleimidopropionamido] hexanoate
(Pierce). A mixture of spleen cells from SWHEL and OT-II mice containing 3 3
104 HEL-binding B cells and 3 3 104 Va2+ CD4+ OT-II T cells was injected
i.v. into recipient mice together with 4–6 mg of HEL2X-OVApep conjugate.
Mice also received 10 mg of OVA emulsified in Alum i.p. To detect HEL-binding
cells, splenocytes were stained with saturating amounts of HEL (100 ng/ml),
followed by Alexa Fluor 647-conjugated anti-HEL (HyHEL9). To detect
affinity-matured SWHEL cells, splenocytes were stained with HEL
3X (50 ng/ml)
followed by HyHEL9 Alexa Fluor 647 as previously described (Phan et al.,
2006). Serum levels of affinity-matured antibody were detected by coating
plates with HELWT or HEL4X (which is bound by the HyHEL10 with the Y53D
mutation but not unmutated HyHEL10) and detected with an anti-IgG1 (see
Supplemental Experimental Procedures).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at doi:10.1016/
j.immuni.2010.07.015.
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